Latest NGM reports update at 2024-03-11: 2023 ∙ 2022 ∙ 2021

NGM Biopharmaceuticals NGM

$ 1.54 0.0%

NGM Biopharmaceuticals Financial Statements 2011-2024 | NGM

Annual Financial Statements NGM Biopharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	127 M	375 M	1.37 B	2.07 B	831 M	-	-	-	-	-	-	-	-
Shares	82.5 M	80 M	77.1 M	68.5 M	50.3 M	-	-	-	-	-	-	-	-
Historical Prices	1.54	4.69	17.7	30.3	18.5	-	-	-	-	-	-	-	-
Net Income	-142 M	-163 M	-120 M	-102 M	-42.8 M	-493 K	-14.2 M	-6.92 M	-	-	-	-	-
Revenue	4.42 M	55.3 M	77.9 M	87.4 M	104 M	109 M	77.1 M	85.6 M	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-151 M	-166 M	-121 M	-104 M	-49.3 M	-4.31 M	-17.4 M	-	-	-	-	-	-
Interest Expense	-234 K	-132 K	-60 K	-593 K	-147 K	199 K	-152 K	-	-	-	-	-	-
EBITDA	-149 M	-162 M	-115 M	-97.3 M	-41.7 M	2.91 M	-11 M	-4.83 M	-	-	-	-	-
Operating Expenses	156 M	222 M	199 M	191 M	153 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	37.8 M	40.5 M	36.9 M	27.2 M	23.6 M	17.3 M	14.8 M	11.8 M	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement NGM Biopharmaceuticals

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	82.7 M	82.5 M	82 M	81.9 M	80.6 M	79.3 M	78 M	78 M	77.4 M	77.1 M	76 M	70.6 M	68.8 M	68.3 M	67.4 M	67 M	65.9 M	61 M	6.81 M	6.94 M	6.53 M	6.2 M	6.13 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-28.8 M	-38.3 M	-47.6 M	-	-47.3 M	-46.5 M	-32.4 M	-	-28.9 M	-36.7 M	-27.5 M	-	-29.8 M	-25.6 M	-19.1 M	-15.9 M	-10.9 M	-7.67 M	-8.27 M	14.2 M	-7.52 M	-3.2 M	-3.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	582 K	1.42 M	2.25 M	-	7.91 M	8.29 M	20.9 M	-	18.6 M	16.8 M	21.6 M	-	23.5 M	19.8 M	24.4 M	31.1 M	21.6 M	25.3 M	25.6 M	47.1 M	20.8 M	22.1 M	18.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-31 M	-40.6 M	-50.2 M	-	-48.3 M	-47.1 M	-32.6 M	-	-29 M	-36.6 M	-27.8 M	-	-30 M	-25.5 M	-20.7 M	-17.3 M	-13 M	-9.71 M	-9.34 M	13.1 M	-8.47 M	-4.19 M	-4.72 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-15 K	-134 K	-37 K	-	78 K	5 K	-45 K	-	35 K	-187 K	187 K	-	-68 K	-471 K	380 K	-	96 K	-6 K	-36 K	-	-14 K	95 K	22 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-30.5 M	-40 M	-49.6 M	-	-47.7 M	-45.7 M	-31.2 M	-	-27.5 M	-35 M	-26.3 M	-	-28.4 M	-23.8 M	-18.9 M	-17.3 M	-11.1 M	-7.81 M	-7.38 M	13.1 M	-6.57 M	-2.49 M	-2.97 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	31.6 M	42 M	52.4 M	-	56.2 M	55.4 M	53.5 M	-	47.6 M	53.4 M	49.4 M	-	53.4 M	45.3 M	45 M	-	34.6 M	35 M	34.9 M	-	29.3 M	26.3 M	23.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	8.67 M	9.65 M	11.6 M	-	10.1 M	9.93 M	10.7 M	-	8.87 M	9.82 M	8.72 M	-	6.46 M	6.79 M	6.6 M	-	5.61 M	6.23 M	5.37 M	-	4.81 M	3.46 M	3.87 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency